

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106754 A1

(51) International Patent Classification:

A61K 39/215 (2006.01) A61P 31/14 (2006.01)
C07K 14/165 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/056028

(22) International Filing Date:

14 November 2024 (14.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/599,500 15 November 2023 (15.11.2023) US
63/602,481 24 November 2023 (24.11.2023) US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(71) Applicant: **BIONTECH SE** [DE/DE]; An der Goldgrube
12, 55131 Mainz (DE).

(72) Inventors: **GÜLER, Alptekin**; c/o BioNTech SE, An der
Goldgrube 12, 55131 Mainz (DE). **VOGEL, Annette**; c/o
BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).
MUIK, Alexander; c/o BioNTech SE, An der Goldgrube
12, 55131 Mainz (DE). **CADIMA COUTO, Carla Iris**;
c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz
(DE). **WALLS, Alexandra**; c/o BioNTech US Inc., 40 Erie
Street, Suite 110, Cambridge, Massachusetts 02139 (US).
PUSHPARAJ, Pradeepa; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE). **FELT, Sébastien Alexandre**;
c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).
LUI, Bonny Gaby; c/o BioNTech SE, An der Goldgrube
12, 55131 Mainz (DE).

(74) Agent: **HINRICHSSEN, Michael** et al.; CHOATE, HALL
& STEWART LLP, Two International Place, Boston, Mass-
achusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CORONAVIRUS VACCINE

(57) Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.



WO 2025/106754 A1